Pharmaceuticals, Biotechnology and Life Sciences
AstraZeneca and MSD’s Lynparza (olaparib) has been approved in the European Union (EU) for the 1st-line maintenance treatment with bevacizumab of patients with homologous recombination deficient (HRD)-positive advanced ovarian cancer.
Expanded indication allows for treatment of women whose advanced ovarian cancer is associated with homologous recombination deficiency (HRD) Zejula is…
Company to host conference call following ASCO presentation on June 2 to discuss updated clinical data DARTMOUTH, Nova Scotia–(BUSINESS WIRE)–IMV…
Transgene can start linical trial of its lead myvac™ candidate TG4050as a potential treatment for ovarian cancer patients after first-linesurgery and chemotherapy
German Merck, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer are dropping the Phase III JAVELIN Ovarian PARP 100 study in which they tested avelumab combined with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, versus an active comparator in treatment-naïve patients with locally advanced or metastatic ovarian cancer (Stage III or Stage IV), as they described in the press release on Wednesday.
DCVAC/OvCa decreased the risk of death in second line treatment of ovarian cancer by 62% Overall survival (OS) increased significantly by…
After the Oasmia Pharmaceutical’s pivotal study OAS 07OVA conducted on ovarian cancer patients with disease relapse, showed that the risks…
The U.S. Food and Drug Administration has approved Tesaro’s Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk (complete or partial response, respectively) in response to platinum-based chemotherapy.
AstraZeneca’s trial treating relapsed ovarian cancer patients with olaparib met its primary endpoint, the company said Tuesday.
Neovacs and Professor Robert Kerbel and his team at the Sunnybrook Research Institute of Toronto, Canada are about to join…